# Pharmacokinetic (PK) Bridging ELISA

#### **PK** -Dupilumab

# For Use with Anti-Dupilumab Monoclonal Antibodies catalog #TZA014 and #TZA015P

This method provides a procedure for carrying out a PK ELISA with Anti-Dupilumab Antibodies, #TZA014 (capture antibody, AbD47091ad) and HRP-conjugated #TZA015P (detection antibody, AbD47092pap), and using dupilumab for the standard curve. The method should always be used in conjunction with product and batch specific information provided with each vial (see product datasheets). This protocol will need to be adjusted for use with different detection methods and immunoassay technology platforms.

### Reagents

- BSA
- HISPEC Assay Diluent (#BUF049)
- Human Serum (Sigma-Aldrich, #H4522)
- PBS
  - 136 mM NaCl
  - 2.68 mM KCl
  - 8.1 mM Na<sub>2</sub>HPO<sub>4</sub>
  - 1.46 mM KH<sub>2</sub>PO<sub>4</sub>
- PBST
- PBS with 0.05% Tween 20 (Merck Millipore, #817072)
- QuantaBlu Fluorogenic Peroxidase Substrate
  (Thermo Fisher Scientific, #15169)

### Materials

- 384-well microtiter plate, black, square flat-bottom wells, for example, Black 384-Well Immuno Plates (Thermo Fisher Scientific, #460518)
- Fluorescence plate reader

96-well plates can be used instead of 384-well plates, black, flat-bottom wells for example, Black 96-Well Immuno Plates (Thermo Fisher Scientific, #437111). For the 96-well format, use 100  $\mu$ l (instead of 20  $\mu$ l) of antigen, antibodies, or substrate and 300  $\mu$ l for the blocking step.

# Method

1. Prepare the capture Anti-Dupilumab Antibody #TZA014 (AbD47091ad) at 1  $\mu$ g/ml in PBS. Coat the required number of wells of a 384-well microtiter plate with 20  $\mu$ l per well of the prepared capture antibody, and incubate overnight at 4°C

2. Wash the microtiter plate five times (5x) with PBST.

3. Block the microtiter plate by adding 100  $\mu$ l 5% BSA in PBST to each well, and then incubate for 1 hr at RT.

4. Wash the microtiter plate 5x with PBST.

5. For the standard curve, prepare a dilution series of dupilumab in 10% human serum in PBST in triplicate. Final concentration of dupilumab should cover the range from 0.01 ng/ml to 10,000 ng/ml. Include a zero dupilumab concentration as the background value.

6. Add 20  $\mu$ l of dupilumab dilution per well (in triplicate for each standard recommended). Add 20  $\mu$ l of each test sample to the other wells (in triplicate for each sample recommended). Incubate for 1 hr at RT.

7. Wash the microtiter plate 5x with PBST.

8. Prepare the HRP-conjugated detection Anti-Dupilumab Antibody TZA015P (AbD47092pap).

 To each well, add 20 µl HRP conjugated detection Anti-Dupilumab Antibody, #TZA015P (AbD47092pap), at 0.5 µg/ml in HISPEC Assay Diluent (#BUF049). Incubate for 1 hr at RT.
 Wash the microtiter plate 10x with PBST.

11. Add 20  $\mu l$  QuantaBlu Fluorogenic Peroxidase Substrate to each well and measure the fluorescence after 30 min.



BIO-RAD is a trademark of Bio-Rad Laboratories, Inc. All trademarks used herein are the property of their respective owner.



Bio-Rad Laboratories, Inc.

Life Science Group bio-rad-antibodies.com

Bulletin 3512 Ver A US/EG

 $(\mathbf{i})$